drugsScienceThe Uncertain Path Forward for Psychedelic MedicineBy Emily MullinScienceSupplements Companies Are Cashing In on the Ozempic WaveBy Kate KnibbsScienceHow Do You Get Drugs to the Brain? Maybe Try a ParasiteBy Bill SullivanScienceThe FDA Just Rejected a Bid for MDMA to Treat PTSDBy Emily MullinGearSemaglutide for the PeopleBy Michael CaloreScienceThe Case for MDMA’s Approval Is Riddled With ProblemsBy Emily MullinThe Big StoryInside the Biggest FBI Sting Operation in HistoryBy Joseph CoxSecurityEventbrite Promoted Illegal Opioid Sales to People Searching for Addiction Recovery HelpBy Matt Burgess and Dhruv MehrotraScienceThe Next Generation of Cancer Drugs Will Be Made in SpaceBy Grace BrowneScienceThey Had PTSD. A Psychedelic Called Ibogaine Helped Them Get BetterBy Emily MullinScienceOzempic Could Also Help You Drink Less AlcoholBy Grace BrowneScienceThe First Crispr Medicine Just Got ApprovedBy Emily MullinScienceWegovy Slashes the Risk of Heart Attack and Stroke in a Landmark TrialBy Emily MullinScienceThe FDA Approves Weight Loss Drug Zepbound, a Wegovy and Ozempic RivalBy Emily MullinScienceCalifornia Nixes a Bill to Decriminalize Plant-Based PsychedelicsBy Celia FordScienceCovid Boosters Can’t Outpace New Mutations. Here’s Why They Still WorkBy Emily MullinScienceOzempic and Wegovy Can Also Protect Your HeartBy Emily MullinCultureAdderall Shortages Are Dragging On—Can Video Games Help?By Celia FordScienceEveryone Was Wrong About AntipsychoticsBy Max G. LevyScienceThe First Pill for Postpartum Depression Is Almost HereBy Emily MullinScienceTicks and the Diseases They Carry Are Spreading. Can This Drug Stamp Them Out?By Maryn McKennaScienceThe US Finally Approved an Over-the-Counter Birth Control Pill. Here’s What to KnowBy Emily MullinSecuritySilk Road’s Second-in-Command Gets 20 Years in PrisonBy Andy GreenbergScienceThe One-Shot Drug That Keeps on DosingBy Max G. LevyMore Stories
